Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | LMNA | P02545 | 6/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.57 |
| ▸ | CCR1 | P32246 | 3/20 | 0.57 |
| ▸ | CCR5 | P51681 | 3/20 | 0.57 |
| ▸ | CCR8 | P51685 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | ALPL | P05186 | 1/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.57 |
| ▸ | ALPI | P09923 | 1/20 | 0.57 |
| ▸ | ALPG | P10696 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | METAP1 | P53582 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5549722 | 0.83 | KDM4E (0.57) | KDM4ELMNAALOX15CCR1CCR5 | |
| SCHEMBL13596181 | 0.80 | KDM4E (0.63) | KDM4ELMNAALOX15CCR1CCR5 | |
| SCHEMBL164554 | 0.79 | — | — | |
| SCHEMBL29700580 | 0.79 | — | — | |
| SCHEMBL24581100 | 0.79 | KDM4E (0.67) | KDM4ELMNAALOX15CCR1CCR5 | |
| SCHEMBL14614567 | 0.79 | TRPV3 (0.57) | KDM4ETDP1RAB9APDE10A | |
| SCHEMBL18769070 | 0.78 | KDM4E (0.65) | KDM4ELMNAALOX15CCR1CCR5 | |
| Hydrochloric Acid SCHEMBL2654743 | 0.77 | LMNA (0.66) | LMNAALOX15TDP1L3MBTL1HTT | |
| Bromide SCHEMBL9039579 | 0.77 | HRH3 (0.62) | LMNAALOX15TDP1L3MBTL1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5552722 | 0.77 | LMNA (0.66) | LMNAALOX15TDP1L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023250157-A9 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023250157-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2023-12-28 | — | — | WO | disclosed |
| US-9233995-B2 | Quinazoline derivatives and quinazoline complex protein kinase inhibitor for inhibiting multiplication of tumor cells and preparation method thereof | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2016-01-12 | — | — | US | disclosed |
| US-20130225811-A1 | QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCE (CN) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225811-A1 | QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF | MAP3K21, MAP3K15, MAP3K14 | KDM4E 1544/4885LMNA 2126/4885ALOX15 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.